Forum Replies Created
- Replies
-
-
- July 30, 2014 at 9:17 pm
I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )
The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment.
-
- July 30, 2014 at 9:17 pm
I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )
The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment.
-
- July 30, 2014 at 9:17 pm
I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )
The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment.
-